These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930 [TBL] [Abstract][Full Text] [Related]
26. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671 [TBL] [Abstract][Full Text] [Related]
27. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253 [TBL] [Abstract][Full Text] [Related]
28. Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma. Amini-Adle M; Khanafer N; Le-Bouar M; Duru G; Dalle S; Thomas L BMC Cancer; 2018 Jul; 18(1):705. PubMed ID: 29970025 [TBL] [Abstract][Full Text] [Related]
29. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Devji T; Levine O; Neupane B; Beyene J; Xie F JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543 [TBL] [Abstract][Full Text] [Related]
30. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting. Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054 [TBL] [Abstract][Full Text] [Related]
31. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577 [TBL] [Abstract][Full Text] [Related]
32. Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. Guida M; Bartolomeo N; Quaresmini D; Quaglino P; Madonna G; Pigozzo J; Di Giacomo AM; Minisini AM; Tucci M; Spagnolo F; Occelli M; Ridolfi L; Queirolo P; De Risi I; Valente M; Sciacovelli AM; Chiarion Sileni V; Ascierto PA; Stigliano L; Strippoli S J Transl Med; 2022 Apr; 20(1):159. PubMed ID: 35382857 [TBL] [Abstract][Full Text] [Related]